SOURCE: Hemostemix Inc.

Hemostemix Inc.

January 28, 2015 09:39 ET

Hemostemix Names Gerald D. Brennan, Jr. to Board of Directors; Announces Management Title Change

CALGARY, AB--(Marketwired - Jan 28, 2015) - Hemostemix Inc. (the "Corporation") (TSX VENTURE: HEM) announced today that its board of directors has appointed Gerald ("Jerry") D. Brennan, Jr. to the board effective immediately. Jerry has more than 20 years of executive management experience in the areas of corporate finance, legal, and general administration. He holds a BABS degree from Marquette University and a JD degree from University of Illinois.

Under Jerry's leadership as vice president of finance and administrative services and chief financial officer (CFO) at Vericel Corporation (formerly Aastrom Biosciences), the company raised $38 million in a series of registered direct offerings. He is currently a director of a private preclinical pharmaceutical company that develops treatments for Duchenne muscular dystrophy and other diseases. Prior to joining Vericel, Jerry served as director of new ventures at Great Lakes Chemical Corporation and CFO of Great Lakes Fine Chemical Division and Monsanto Pharma Tech. Before that, Jerry was CFO and chief operating officer (COO) of Capcom Coin-Op, Inc., and he served in various management positions at Tupperware North America, including general counsel and vice president of distributor operations and administration. He has also served previously as tax counsel at Premark and as a tax manager at Coopers & Lybrand.

"Jerry's depth of experience will be a considerable asset to the company as we develop strategies for finance and business in the short term and product commercialization and global distribution in the long term," said C.W. (Bill) Baker, chairman of the board.

Hemostemix also announced that Dr. Elmar Burchardt, CEO, assumed the additional title of president.

About Hemostemix
Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. Hemostemix Inc. is traded on the Toronto Stock Exchange Venture under the trading symbol v.HEM.

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Qualifying Transaction and associated transactions and has neither approved nor disapproved of the contents of this press release.

Contact Information

  • For further information, please contact:

    Hemostemix Inc.

    Dr. Elmar Burchardt
    President and CEO
    Phone: (617) 500-8401

    C.W. (Bill) Baker
    Chairman of the Board
    Phone: (403) 818-7672